Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

WASP

Financiado

Cerrado

Wide Spectral Range Photonic Glucometer

Diabetic patients (around 8.6% of the western population) must constantly monitor their blood glucose level (BGL) with a continuous glucose monitoring (CGM) device. This social need has already been addressed by some companies, wi... ver más

30/04/2017

CSIC

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 552M€

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-04-30

ERC-PoC-2015: ERC Proof of Concept Grant Scope:Objectives

I+D

Cerrada hace 10 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

CSIC

149.97K€ | Lider

GRUP BAUCELLS ALIMENTACIO

681.26K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 21 meses Fecha Inicio: 2015-07-09
Fecha Fin: 2017-04-30

Líder del proyecto

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 552M€

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Diabetic patients (around 8.6% of the western population) must constantly monitor their blood glucose level (BGL) with a continuous glucose monitoring (CGM) device. This social need has already been addressed by some companies, with an overall compound annual growth rate (CAGR) for this market (from 2014 through 2019) of 19.6%. Besides such highly attractive market possibilities, to date none of the commercial CGMs can provide accuracy below 20%. This is a non-assumable risk for the users. In addition, the readout medical device can only be used for glucose sensing, severely limiting its use for early detection of other analytes of interest. WASP POC aims to bring into the market the next generation of CGMs which makes use of light as interrogation mechanism. In this approach, and with the appropriate multi-purpose medical readout device, accuracies of 10% will be attained. It is the vision of the WASP team that this approach will represent a game-changing player in the market of CGMs. Important is to mention that high technology does not necessary means huge fabrication costs, and WASP will only make use of mass-production technologies and well established measurement protocols (developed in the ERC Starting Grant HIP-LAB). To determine the market impact of WASP, a throughout market study will be pursued, considering the advantages of the WASP concept as opposite to the competitors. Additionally, a preliminary industrial overview for WASP massive production will be pursued. This preliminary evaluation will take into account production series in the range of 3-300 million units per year, considering all key factors in a real productive environment such as direct costs, replacement costs, etc. WASP is firmly grounded on already owned IPR related to this topic (patent PCT/ES2011/070011). In addition, a risk assessment procedure has been established allowing the choice of the best route towards either starting-up or licensing the concept to a major player.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores